The introduction of biologic therapies has led to dramatic improvements in the management
of moderate-to-severe psoriasis. Even though the efficacy and safety of the newer biologic …

The introduction of biologic agents for the treatment of psoriasis has revolutionized the
current treatment landscape, targeting cytokines in the interleukin (IL)-23/IL-17 pathway and …

Introduction Psoriasis is a chronic inflammatory immune condition. Treatments for psoriasis
vary with disease severity, ranging from topicals to systemic biologic agents. The …

Psoriasis is a chronic inflammatory skin disease affecting 2–3% of the global population.
Traditional systemic treatments, such as methotrexate, cyclosporine, acitretin and fumaric …

Introduction Although some factors associated with asthma symptom deterioration and risk
of exacerbation have been identified, these are not yet fully characterised. We conducted a …

Background Understanding the economic value of deucravacitinib and apremilast could
assist treatment decision-making for patients with moderate to severe plaque psoriasis …

Introduction Nowadays, despite the wide availability of biological drugs and apremilast for
psoriasis management, there is always a need for new therapies to customize the …

Psoriasis is a chronic, immune‐mediated disorder characterized by immune regulation
disorders and abnormal keratinocyte proliferation. Deucravacitinib (Deu), a selective oral …

Methods This placebo-anchored matching-adjusted indirect comparison (MAIC) analysis
utilized data from UltIMMa-1/2 risankizumab and POETYK PSO-1/2 deucravacitinib trials …

Expanding the systemic treatment options for patients with psoriasis, deucravacitinib, an
oral, selective, allosteric tyrosine kinase 2 inhibitor is approved in the United States …